Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Feb 1;8(1):49.
doi: 10.1038/s41392-023-01321-x.

Gonadotropin releasing hormone (GnRH): a hormone therapy boosts cognition in Down syndrome and dementia

Keenan Sterling #  1 , Ruixue Cao #  2 , Weihong Song  3   4
Affiliations
Comment

Gonadotropin releasing hormone (GnRH): a hormone therapy boosts cognition in Down syndrome and dementia

Keenan Sterling et al. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
The therapeutic effects of GnRH in DS. a Developmental timeline showing the onset and progression of pathology in Ts65Dn mice, as reported in the highlighted paper. b Summary of the intervention strategies to rescue GnRH and their therapeutic effects in Ts65Dn mice. c Diagram showing how GnRH could boost cognition in humans. GnRH therapy may restore network dysfunction in the brain by strengthening the connectivity between cortical areas (Cx) that are hypoconnected in DS, and weakening abnormally hyperconnected subcortical areas, such as the hippocampus (Hpx) and amygdala (Amy). GnRH may also act to improve information processing at the cellular level by modulating neuronal excitability. Image created with BioRender.com. WT-POA wild-type pre-optic area, fEPSPs functional excitatory postsynaptic potentials
See this image and copyright information in PMC

Comment on

  • GnRH replacement rescues cognition in Down syndrome.
    Manfredi-Lozano M, Leysen V, Adamo M, Paiva I, Rovera R, Pignat JM, Timzoura FE, Candlish M, Eddarkaoui S, Malone SA, Silva MSB, Trova S, Imbernon M, Decoster L, Cotellessa L, Tena-Sempere M, Claret M, Paoloni-Giacobino A, Plassard D, Paccou E, Vionnet N, Acierno J, Maceski AM, Lutti A, Pfrieger F, Rasika S, Santoni F, Boehm U, Ciofi P, Buée L, Haddjeri N, Boutillier AL, Kuhle J, Messina A, Draganski B, Giacobini P, Pitteloud N, Prevot V. Manfredi-Lozano M, et al. Science. 2022 Sep 2;377(6610):eabq4515. doi: 10.1126/science.abq4515. Epub 2022 Sep 2. Science. 2022. PMID: 36048943 Free PMC article.

References

    1. Manfredi-Lozano MA-O, et al. GnRH replacement rescues cognition in Down syndrome. Science. 2022;377:eabq4515. doi: 10.1126/science.abq4515. - DOI - PMC - PubMed
    1. Zheng Q, et al. USP25 inhibition ameliorates Alzheimer’s pathology through the regulation of APP processing and Abeta generation. J. Clin. Investig. 2022;132:e152170. doi: 10.1172/JCI152170. - DOI - PMC - PubMed
    1. Nijjar RK, Murphy C. Olfactory impairment increases as a function of age in persons with Down syndrome. Neurobiol. Aging. 2002;23:65–73. doi: 10.1016/S0197-4580(01)00263-9. - DOI - PubMed
    1. Boehm U, et al. Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism-pathogenesis, diagnosis and treatment. Nat. Rev. Endocrinol. 2015;11:547–564. doi: 10.1038/nrendo.2015.112. - DOI - PubMed
    1. Skrapits K, et al. The cryptic gonadotropin-releasing hormone neuronal system of human basal ganglia. eLife. 2021;10:e67714. doi: 10.7554/eLife.67714. - DOI - PMC - PubMed

Publication types

Substances